Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales

Ono Pharmaceutical’s group revenue in April-December surged nearly 25% year on year on the back of strong performances from the PD-1 inhibitor Opdivo (nivolumab) and the SGLT2 inhibitor Forxiga (dapagliflozin). In the first nine months of FY2022, the company logged...read more